+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

NMDA Receptor Antagonist -Pipeline Insight, 2019

  • ID: 4745350
  • Drug Pipelines
  • January 2019
  • Region: Global
  • 120 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Alkermes plc
  • Astrazeneca
  • Avanir Pharmaceuticals
  • Biohaven Pharmaceutical
  • Cerecor, Inc.
  • GNT Pharma
  • MORE
“NMDA Receptor Antagonist - Pipeline Insight, 2019” report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across “NMDA Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for “NMDA Receptor Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for “NMDA Receptor Antagonist
The report assesses the active NMDA Receptor Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • Provides a snapshot of the therapeutics pipeline activity for “NMDA Receptor Antagonist
  • Features the NMDA Receptor Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of NMDA Receptor Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across “NMDA Receptor Antagonist
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across NMDA Receptor Antagonist to formulate effective R&D strategies
  • Assess challenges and opportunities that influence NMDA Receptor Antagonist research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for “NMDA Receptor Antagonist
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for NMDA Receptor Antagonist to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
  • Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alkermes plc
  • Astrazeneca
  • Avanir Pharmaceuticals
  • Biohaven Pharmaceutical
  • Cerecor, Inc.
  • GNT Pharma
  • MORE
1. Report Introduction

2. NMDA Receptor Antagonist - Overview

3. Pipeline Therapeutics
  • An Overview of Pipeline Products for NMDA Receptor Antagonist
4. Comparative Analysis

5. NMDA Receptor Antagonist Pipeline Products in Clinical Stages
5.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Other product profiles in the detailed report…..

6. NMDA Receptor Antagonist Pipeline Products in Non-clinical Stages
6.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Other product profiles in the detailed report…..

7. Therapeutic Assessment: Active Products
  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline Products
8.1 Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation
Appendix

Report Methodology

Consulting Services

Disclaimer

About the publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Biohaven Pharmaceutical
  • Anavex Life Science Corp.
  • Alkermes plc
  • Astrazeneca
  • Auris Medical
  • Avanir Pharmaceuticals
  • BioCrea GmbH
  • Bristol-Myers Squibb
  • Cerecor, Inc.
  • e-Therapeutics
  • GNT Pharma
  • Johnson & Johnson
  • Merz Pharmaceutical
  • LACHESIS BIOSCIENCES
Note: Product cover images may vary from those shown
Adroll
adroll